Jennifer Doudna’s Berkeley institute eyes corporate deal to help set CRISPR standard for treating hundreds of diseases

Potential treatments for two deadly rare diseases in children could be demonstration projects for the new center and its partnership with Danaher Corp.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks